

Key regulatory approval milestones passed

Second quarter, 1 August – 31 October 2024


- **Net sales** amounted to SEK 1,855k (2,890k).
- **Operating result (EBIT)** amounted to SEK -6,007k (-3,409k).
- **Net result for the period** amounted to SEK -5,951k (-3,256k).
- **Earnings per share before dilution** amounted to SEK -1.48 (-0.81). Earnings per share after dilution amounted to SEK -1.48 (-0.81).
- **Cash flow from operating activities** amounted to SEK -6,145k (-4,143k).
- **Net cash flow** amounted to SEK -9,537k (-11,560k).
- We have passed two important milestones regarding regulatory approval. The technical documentation has been approved and we have also resolved outstanding deviations from the review of our quality system (ISO 13485) which was done in July and August.

First half year, 1 May - 31 October 2024

- **Net sales** increased to SEK 3,530k (6,317k).
- **Operating result (EBIT)** amounted to SEK -13,627k (-8,821k).
- **Net result for the period** amounted to SEK -13,480k (-8,255k).
- **Earnings per share** amounted to -3.35 (-2.05) SEK. Earnings per share after dilution amounted to -3.35 (-2.05) SEK.
- **Cash flow from operating activities** amounted to SEK -3,665k (-10,013k).
- **Net cash flow** amounted to SEK -9,746k (-23,930k).

kSEK	1 Aug 2024- 31 Oct 2024	1 Aug 2023- 31 Oct 2023	1 May 2024 - 31 Oct 2024	1 May 2023 - 31 Oct 2023	1 Nov 2023- 31 Oct 2024	1 May 2023 - 30 Apr 2024
Net sales	1,855	2,890	3,530	6,317	12,672	14,369
Operating result before depreciations, EBITDA	-4,871	-2,417	-11,341	-6,840	-17,287	-12,785
Operating result, EBIT	-6,007	-3,409	-13,627	-8,821	-21,628	-16,822
Net result for the period	-5,951	-3,256	-13,480	-8,255	-20,905	-15,681
Earnings per share before dilution, SEK	-1.48	-0.81	-3.35	-2.05	-5.19	-3.89
Earnings per share after dilution, SEK	-1.48	-0.81	-3.35	-2.05	-5.19	-3.89
Net cashflow	-9,537	-11,560	-9,746	-23,930	-26,562	-40,746

The amounts in this report do not always agree exactly due to rounding. Comparison figures presented in this report refer to previous year, unless otherwise stated.



CEO's statement



During the quarter, we have continued to focus on the CE marking of Glucore Diagnostics for leukemia and passed two important milestones. The technical documentation has been approved and we have also resolved outstanding deviations from the review of the quality management system that was carried out in July and August. We are now awaiting the final decision and the sales launch for clinical use is still estimated to be February 2025. The sales launch for clinical use is still estimated to be February 2025. Our solution enables, the classification of subgroups within different forms of cancer with the aim of improving diagnostics and treatment. We remain unaware of any other IVDR-approved software in this area.

Net sales during the second quarter amounted to SEK 1,855 (2,890) k, which is a decrease of 36 percent. Differences between quarters occur, and this quarter the difference is largely due to the fact that during the

corresponding quarter last year, an unusually large number of multi-year deals were completed, involving agreements where the license period extends over several years. In the case of sales of multi-year licenses, these are not accrued, but the entire sales sum affects the revenue in the quarter in which they are invoiced, whereby the revenue can vary greatly between quarters. The transactions are booked on the invoicing date and thus affect the first quarter of the previous year positively and the current quarter negatively.

After the end of the period, in November we launched a new version of Glucore Omics Explorer. The updates mean significantly improved functionality for analyzing and visualizing integer data. A function growth that is in demand by our customers.

Diagnostics

Sales and marketing are actively underway with both the leukemia model and the lung cancer model. We work both with direct sales to the target group and marketing through, for example, presentations at scientific conferences. During the quarter, we also carried out a European campaign linked to Glucore Insights with a focus on Germany, Benelux and Italy. In September we exhibited at the European Society for Medical Oncology (ESMO) conference in Barcelona to show the lung model to a wider audience.

We have also presented results at two conferences. At *"The Molecular Analysis for Precision Oncology Congress 2024"*, in London, England, the lung cancer model was presented in a scientific poster. The results show that Qlucore Insights can effectively analyze lung samples and help classify them. The results were produced together with our partner, the Institute of Pathology in Heidelberg and the main author is Alejandro Pallares Robles. The model enables the identification of different forms of lung cancer and the determination of whether it is a metastasis.

We also presented results for the pediatric leukemia model (BCP-ALL) at the *"AACR special conference in cancer research: advances in pediatric cancer research"*, which was held in Toronto, Canada.

According to the IVDR regulations for medical devices, the process of achieving CE marking is a requirement to be used for diagnostics in healthcare. Given the positive feedback from our contracted Notified Body (BSI), the focus is now on preparing for launch and completing final verifications pending the formal certificate. Estimated time for regulatory approval (CE marking) for childhood acute lymphoblastic leukemia (BCP-ALL) is February 2025. For future models, we also envision a high degree of reuse of the investments already made in Qlucore Diagnostics.

The work on the lung cancer, bladder cancer and adult acute myeloid leukemia (AML) projects is also ongoing. All forms of cancer represent strategically important therapeutic areas with great medical needs for improved diagnostics.

The two EU-funded projects in cardiovascular diseases continue to develop positively, further illustrating that our solutions are relevant for many different disease areas.

Global landscape

Global uncertainty with the deteriorating geopolitical situation and the weak economy, has not affected operations during the period, as far as we can judge.

Our technical and regulatory position is good. To be able to scale up quickly and ensure long-term development, we are evaluating both strategic and operational alternatives as well as different financing solutions to secure liquidity.

Carl-Johan Ivarsson, CEO

Financial overview

Net sales

- Net sales for the second quarter amounted to SEK 1,855k (2,890k), a decrease of 36 percent compared to the corresponding period last year.
- Net sales for the first six months amounted to SEK 3,530k (6,317k), representing a decrease of 44% compared to the same period previous year.
- We have and will have differences between quarters depending on a combination of the

result of new sales and variations in renewal sales. In the case of sales of multi-year licenses, these are not accrued, but the entire sales sum affects the revenue in the quarter in which they are invoiced, whereby the revenue can vary greatly between quarters. The transactions are booked on the invoicing date and thus affect the first quarter of the previous year positively and the current quarter negatively.

Operating result and Net result

- The operating result for the second quarter amounted to SEK -6,007k (-3,409k) and for the first six months to SEK -13,627k (-8,821k).
- The net result for the second quarter amounted to SEK -5,951k (-3,256k) whilst

the net result for the first six months amounted to SEK -13,480k (-8,255k).

- Income taxes charges pertain to the subsidiary in the USA.

Cash flow

- Cash flow from operating activities during the second quarter amounted to SEK -6,145k (-4,143k) and for the first six months to SEK -3,655k (-10,013k). The negative difference in the second quarter is mainly due to the negative cash flow from operations. The positive difference for the half year is mainly due to the payment in May from the EU.
- The net cash flow for the second quarter amounted to SEK -9,537k (-11,560k) and for the first six months to SEK -9,746k

(-23,930k). The difference is due to a combination of lower investments in intangible assets and positive working capital for the first six months compared to the corresponding period last year.

- Cash and Cash equivalents at the end of the period amounted to SEK 18,889k (45,591k). Total assets amounted to SEK 83,652k (97,389k) at the closing day.

Financial position

- Investments during the second quarter amounted to SEK 3,023k (7,098k) and for the first six months to SEK 5,344k (13,379k). Most of the investments consist of capitalised costs for development work. The difference between the quarters is due to implemented cost savings and thus also lower development costs to balance.

- The equity amounted to SEK 65,606k at the end of the report period compared to SEK 86,549k last year.

Other significant events

The technical documentation has been approved by our Notified Body, which is an essential milestone for the market introduction of Qlucore Diagnostics to be carried out according to plan in February 2025.

Employees

At the end of the reporting period, the number of employees expressed as full-time equivalents amounted to 21 (22). The average number of employees during the quarter was 20 (22).

Parent company

The parent company in Sweden manages product development, business development and global marketing as well as providing head office functions such as management and administration.

The parent company is also responsible for marketing and sales to customers in Europe and non-American countries. The subsidiary in the United States is responsible for marketing and sales to customers in the American market.

The parent company charges direct costs and part of indirect costs to the subsidiary in the United States. The parent company reported a net result for the second quarter amounting to SEK -5,948k (-3,265k) and for the first six months to SEK -13,471k (-8,293k). At the end of the reporting period, cash and cash equivalents amounted to SEK 18,828k (43,029k).

Organization

No organizational changes were implemented during the quarter.

Outstanding Incentive Program

On September 20, 2022, the annual general meeting decided on an issue of 82,000 warrants for employees with redemption in November 2025 for SEK 45 per share. 55,045

warrants were subscribed for. If all warrants are exercised for the subscription of shares, the company's registered share capital will increase by SEK 15,574 and the dilution effect will be approximately 2 percent.

Subsequent events

At the beginning of November, we received positive feedback from our Notified Body (BSI) regarding our quality system, where they announced that they approve our resolution of outstanding deviations from the review in July and August. In conclusion, the work with the technical information for QD 1.0 and the quality management system has now been reviewed and there are no outstanding questions from our Notified Body. Now the formal decision on their part remains.

Qlucore Omics Explorer 3.10 was launched in November. The new release includes a comprehensive suite of methods to better analyze integer data.

Outlook/Earnings Forecast

Qlucore does not provide any market outlook, nor any business performance forecasts.

Auditor's review of the report

The interim report has not been audited by the auditors of Qlucore AB.

Company information

Qlucore AB (publ), 556719-3528, is a public limited company with residence in Lund, Sweden.

For additional information, please contact Carl-Johan Ivarsson, CEO of Qlucore, at +46 46 286 31 10 or carl-johan.ivarsson@qlucore.com

Financial calendar

Interim report 1 November – 31 January: 27 February 2025

Year-end report: 28 May 2025

Annual general meeting

The Annual General Meeting will be held on September 10, 2025, at 11:00 a.m. in the company's office in Lund.

Declaration of the Board

The Board of Directors certify that this interim report presents a true and fair overview of the Group's and the Parent Company's operations, financial position, and results of operations, and describes the significant risks and uncertainties facing the Parent Company and the companies belonging to the Group.

The board of Qlucore AB (publ), Lund 2024-11-28

Pia Gideon, Chairman

Carl-Johan Ivarsson, CEO

Thoas Fioretos

Magnus Fontes

Boel Sundvall

Helle Fisker

Lars Höckenström

About Qlucore

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore's mission is to make it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is an easy-to-use bioinformatics software for research in the life science, plant and biotech industry, as well as in academia.

Qlucore Diagnostics and Qlucore Insights software are platforms with built-in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 at Lund University, Sweden currently has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia.

This information is information that Qlucore AB is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the agency of the contact persons set out above, on November 28, 2024, at 18:30 CET

Income statement, consolidated

kSEK	1 Aug 2024- 31 Oct 2024	1 Aug 2023- 31 Oct 2023	1 May 2024 - 31 Oct 2024	1 May 2023 - 31 Oct 2023	1 Nov 2023- 31 Oct 2024	1 May 2023 - 30 Apr 2024
Net sales	1,855	2,890	3,530	6,317	11,583	14,369
Capitalised development costs	3,023	6,959	5,344	13,262	14,413	22,331
Other income	2,145	563	3,208	1,671	4,343	2,806
	7,023	10,413	12,082	21,250	30,338	39,506
Other external expenses	-5,529	-6,371	-9,587	-13,527	-18,406	-22,347
Personnel costs	-6,245	-6,374	-13,582	-14,315	-28,569	-29,302
Depreciations	-1,136	-991	-2,286	-1,981	-4,341	-4,036
Other costs	-121	-85	-254	-248	-649	-643
Operating result	-6,007	-3,409	-13,627	-8,821	-21,628	-16,822
Interest income	147	254	324	764	1,081	1,521
Interest expense	-83	-91	-160	-179	-335	-353
Financial items net	64	163	163	585	746	1,168
Result before tax	-5,943	-3,246	-13,464	-8,236	-20,881	-15,654
Income taxes	-8	-10	-16	-19	-24	-27
Net result for the period	-5,951	-3,256	-13,480	-8,255	-20,905	-15,681
Earning per share (SEK)	-1.48	-0.81	-3.35	-2.05	-5.19	-3.89
Earning per share after dilution (SEK)	-1.48	-0.81	-3.35	-2.05	-5.19	-3.89
Average number of shares before dilution	4,028,060	4,028,060	4,028,060	4,028,060	4,028,060	4,028,060
Average number of shares after dilution	4,110,060	4,159,560	4,110,060	4,159,560	4,101,810	4,151,310

Balance sheet condensed, consolidated

kSEK	31 Oct 2024	31 Oct 2023	30 Apr 2024
Assets			
<i>Fixed assets</i>			
Capitalised development costs	56,820	46,465	53,645
Patent	1	1	1
Equipment	244	454	362
Total fixed assets	57,065	46,921	54,008
<i>Current assets</i>			
Account receivables	2,462	2,875	4,242
Other receivables	5,236	2,002	3,139
Cash and cash equivalents	18,889	45,591	28,619
Total current assets	26,587	50,468	36,001
Total assets	83,652	97,389	90,008
Equity and liabilities			
<i>Equity</i>			
Share capital	765	765	765
Other paid in capital	131,944	131,944	131,944
Other equity, incl net result for year	-67,103	-46,160	-53,599
Total equity	65,606	86,549	79,110
<i>Long term liabilities</i>			
Debt to lenders	2,000	3,183	2,000
Long term liabilities	2,000	3,183	2,000
<i>Short term liabilities</i>			
Debt to lenders	446	738	1,183
Account payables	1,131	2,485	2,157
Other short term liabilities	14,469	4,434	5,558
Short term liabilities	16,046	7,657	8,898
Total equity and liabilities	83,652	97,389	90,008

Changes in equity, consolidated

kSEK	31 Oct 2024	31 Oct 2023	30 Apr 2024
Opening balance	79,110	94,732	94,732
Currency translation adjustments	-25	72	59
Net result for the year	-13,480	-8,255	-15,681
Closing balance	65,606	86,549	79,110

Cash flow statement, consolidated

kSEK	1 Aug 2024- 31 Oct 2024	1 Aug 2023- 31 Oct 2023	1 May 2024 - 31 Oct 2024	1 May 2023 - 31 Oct 2023	1 Nov 2023- 31 Oct 2024	1 May 2023 - 30 Apr 2024
<i>Operating activities</i>						
Result before tax	-5,943	-3,246	-13,464	-8,236	-20,881	-15,654
Depreciations	1,136	991	2,286	1,981	4,341	4,036
Adjustment other non-cash items	12	185	-40	280	103	423
Income taxes paid	-8	-10	-16	-19	-24	-27
Cash flow from operating activities before change in working capital	-4,802	-2,079	-11,234	-5,995	-16,460	-11,221
Change in accounts receivable	120	451	1,781	-673	414	-2,040
Change in other receivables	897	-440	-2,097	-96	-3,234	-1,233
Change in accounts payable	-45	-1,117	-1,027	-1,874	-1,354	-2,202
Change in other short term liabilities	-2,315	-957	8,912	-1,376	10,035	-252
Cash flow from working capital	-1,343	-2,064	7,569	-4,019	5,860	-5,727
Cash flow from operating activities	-6,145	-4,143	-3,665	-10,013	-10,600	-16,949
Investment in intangible assets	-3,023	-7,010	-5,344	-13,262	-14,413	-22,331
Investment in tangible assets	0	-88	0	-118	-74	-192
Cash flow from investment activities	-3,023	-7,098	-5,344	-13,379	-14,487	-22,522
Repayment of borrowing	-369	-319	-738	-538	-1,475	-1,275
Cash flow from financing activities	-369	-319	-738	-538	-1,475	-1,275
Net cash flow	-9,537	-11,560	-9,746	-23,930	-26,562	-40,746
Cash & cash equivalents, beginning of period	28,434	57,231	28,619	69,732	45,591	69,732
Exchange rate differences cash & cash equivalents	-8	-80	16	-210	-140	-366
Cash & cash equivalents, end of period	18,889	45,591	18,889	45,591	18,889	28,619
Net change in cash & cash equivalents	-9,537	-11,560	-9,746	-23,930	-26,562	-40,746
Paid interest expenses	-60	-91	-131	-179	-305	-353

Income statement, parent company

kSEK	1 Aug 2024- 31 Oct 2024	1 Aug 2023- 31 Oct 2023	1 May 2024 - 31 Oct 2024	1 May 2023 - 31 Oct 2023	1 May 2023 - 30 Apr 2024
Net sales	521	1,510	815	3,387	8,262
Capitalised development costs	3,023	6,959	5,344	13,262	22,331
Other income	2,145	563	3,208	1,671	2,806
	5,689	9,033	9,367	18,320	33,399
Other external expenses	-5,105	-5,963	-8,712	-12,623	-20,641
Personnel costs	-5,349	-5,425	-11,770	-12,354	-25,015
Depreciations	-1,133	-987	-2,278	-1,973	-4,020
Other costs	-121	-85	-254	-248	-643
Operating result	-6,019	-3,428	-13,647	-8,878	-16,921
Interest income	147	254	324	764	1,550
Interest expense	-77	-91	-148	-179	-353
Total financial items, net	71	163	176	585	1,197
Result before tax	-5,948	-3,265	-13,471	-8,293	-15,723
Income taxes	0	0	0	0	0
Net result for the period	-5,948	-3,265	-13,471	-8,293	-15,723

Balance sheet condensed, parent company

kSEK	31 Oct 2024	31 Oct 2023	30 Apr 2024
Assets			
<i>Fixed assets</i>			
Capitalised development costs	56,820	46,465	53,645
Patent	1	1	1
Equipment	232	425	341
Shares in subsidiaries	1	1	1
Total fixed assets	57,053	46,892	53,988
<i>Current assets</i>			
Accounts receivable	1,452	1,198	1,930
Other receivables	5,296	5,134	4,548
Cash and cash equivalents	18,828	43,029	28,027
Total current assets	25,576	49,362	34,504
Total assets	82,629	96,253	88,492
Equity and liabilities			
<i>Restricted equity</i>			
Share capital	765	765	765
Reserve for development costs	56,820	46,312	53,645
	57,585	47,077	54,410
<i>Unrestricted equity</i>			
Other paid in capital	131,944	131,944	131,944
Other equity, incl net result for the year	-124,862	-93,452	-108,215
	7,082	38,491	23,728
Total equity	64,667	85,568	78,138
<i>Long term liabilities</i>			
Debt to credit institutions	2,000	3,183	2,000
Long term liabilities	2,000	3,183	2,000
<i>Short term liabilities</i>			
Debt to credit institutions	446	738	1,183
Account payables	1,122	2,385	2,147
Other short term liabilities	14,394	4,380	5,024
Short term liabilities	15,962	7,502	8,354
Total equity and liabilities	82,629	96,253	88,492

Changes in equity, parent company

kSEK	31 Oct 2024	31 Oct 2023	30 Apr 2024
Opening balance	78,138	93,861	93,861
Net result for the year	-13,471	-8,293	-15,723
Closing balance	64,667	85,568	78,138

Cash flow statement, parent company

kSEK	1 Aug 2024- 31 Oct 2024	1 Aug 2023- 31 Oct 2023	1 May 2024 - 31 Oct 2024	1 May 2023 - 31 Oct 2023	1 May 2023 - 30 Apr 2024
<i>Operating activities</i>					
Result before tax	-5,948	-3,265	-13,471	-8,293	-15,723
Depreciations	1,133	987	2,278	1,973	4,020
Adjustment other non-cash items	8	131	-16	210	366
Cash flow from operating activities before change in	-4,808	-2,147	-11,209	-6,109	-11,337
Change in accounts receivable	284	-318	478	-549	-1,280
Change in other receivables	1,299	-208	-748	-290	296
Change in accounts payable	-42	-1,143	-1,025	-1,959	-2,197
Change in other short term	-2,335	-985	9,370	-1,315	-671
Cash flow from working capital	-793	-2,653	8,076	-4,113	-3,852
Cash flow from operating activities	-5,601	-4,800	-3,133	-10,223	-15,189
Investment in intangible assets	-3,023	-7,010	-5,344	-13,262	-22,331
Investment in tangible assets	0	-94	0	-118	-192
Cash flow from investment activities	-3,023	-7,104	-5,344	-13,379	-22,522
Financing activities					
Repayment of borrowing	-369	-319	-738	-538	-1,275
Cash flow from financing activities	-369	-319	-738	-538	-1,275
Net cash flow	-8,993	-12,223	-9,215	-24,139	-38,986
Cash & cash equivalents, beginning of period	27,829	55,332	28,027	67,379	67,379
Exchange rate differences cash & cash equivalents	-8	-80	16	-210	-366
Cash & cash equivalents, end of	18,828	43,029	18,828	43,029	28,027
Net change in cash & cash	-8,993	-12,223	-9,215	-24,139	-38,986
Paid interest expenses	-60	-91	-131	-179	-353

Disclosures, accounting policies and risk factors

Accounting policies

The interim report has been prepared in accordance with BFNAR 2012:1, Annual report and consolidated report K3. Accounting policies applied in this report are consistent with those described in the most recent annual report 2023/2024.

The parent company has an income tax deficit of SEK 54,682k at the start of the financial year, that may reduce income tax burden going forward provided a future taxable income. The deferred tax receivable is not recognized in the balance sheet.

Multi-year sales and seasonal variations

Qlucore Omics Explorer and Qlucore Insights are licensed to customers for a fee. The normal term is one year. The customers have the option to purchase multiyear licenses. In those cases, the sales revenue for the whole period is recognized fully at the time the

contract is entered, as rights and obligations are transferred to the buyer at that time as the contract is not terminable. This creates a positive impact in the year of sales and a negative impact one or several years ahead.

Risks and uncertainties

Qlucore's operations are exposed to different types of risk. The Parent Company's risks and uncertainties are the same as those described for the Group. Continuously identifying and evaluating risks is a natural and integrated part of the operations, thus enabling us to control, limit and manage prioritized risks in a proactive manner. Risks are managed daily, and risks are divided into financial and other risks.

Financial risk includes market risk, credit risk and liquidity risk. Market risks include exchange rate risks and interest risks. Exchange rate risk occurs from various currency exposures related to transactions and translations. Qlucore is exposed to exchange rates risks as the sales are mainly denominated in EUR, USD, SEK, and GBP whilst the costs are primarily in SEK or USD thus an exposure exists in these currencies. Interest risk is about changes in the interest rate impacting the cost of debt and income from financial instruments. The impact of changes in interest rates is limited. Liquidity risk is associated with ensuring that payment commitments are fulfilled. Liquidity is monitored frequently to avoid situations resulting in delayed payments. Qlucores operations have been financed by new issues,

grants, loans and overdrafts. If Qlucore is unable to obtain financing on favourable or acceptable terms or at all, this may have a negative effect on Qlucore's business. Credit risk is the risk that the counterparties are unable to pay their liabilities. Outstanding balances are monitored continuously.

Other risks comprise changes in demand from the customers, changes in competition, development of the global economy, development of technology, legislation and other regulatory changes that may impact the performance of Qlucore. Development of diagnostic products according to IVDR regulation is associated with high risk, as significant financial resources are invested in the products and launch can only take place after approval. Further, hampered reputation of Qlucore among customers or within the society because of violations of laws and regulations in the operations, quality in products offered to the customers as well as the ability to attract and retain qualified personnel are other risk areas that may impact the performance of Qlucore.

Additional information on risks and uncertainties are disclosed in the prospectus on the company's website www.qlucore.com.

Key figures

kSEK	1 Aug 2024- 31 Oct 2024	1 Aug 2023- 31 Oct 2023	1 May 2024 - 31 Oct 2024	1 May 2023 - 31 Oct 2023	1 Nov 2023- 31 Oct 2024	1 May 2023 - 30 Apr 2024
Net sales	1,855	2,890	3,530	6,317	12,672	14,369
Net sales growth, %	-35.8%	-4.4%	-44.1%	9.2%	-5.0%	13.4%
Operating result (EBIT)	-6,007	-3,409	-13,627	-8,821	-21,628	-16,822
Operating result (EBIT) margin %	-150.2%	-98.7%	-202.2%	-110.4%	-135.8%	-97.9%
Operating result bef. Depreciations (EBITDA)	-4,871	-2,417	-11,341	-6,840	-17,287	-12,785
Operating result bef. depreciations (EBITDA),	-121.8%	-70.0%	-168.3%	-85.6%	-108.5%	-74.4%
Net result for the period	-5,951	-3,256	-13,480	-8,255	-20,905	-15,681
Cash flow from operating activities	-6,145	-4,143	-3,665	-10,013	-10,600	-16,949
Net cashflow	-9,537	-11,560	-9,746	-23,930	-26,562	-40,746
Equity ratio, %	78.4%	89.0%	78.4%	88.9%	86.0%	87.9%
Capital employed	68,052	90,469	68,052	90,469	59,876	82,293
Return on equity	-28.4%	-16.1%	-28.4%	-16.1%	-21.8%	-17.6%
Return on capital employed	-33.3%	-13.7%	-27.3%	-15.4%	-20.9%	-16.9%
Net debt (-) / Net cash (+)	16,443	41,670	16,443	41,670	209	25,436
Debt vs equity ratio	27.6%	12.4%	27.5%	12.5%	16.3%	13.8%
Earning per share, before dilution, SEK	-1.48	-0.81	-3.35	-2.05	-5.19	-3.89
Earning per share, after dilution, SEK	-1.48	-0.81	-3.35	-2.05	-5.19	-3.89
Equity per share, before dilution, SEK	16.82	21.82	16.29	21.49	14.44	19.64
Equity per share, after dilution, SEK	16.42	21.13	15.77	20.81	14.14	19.18
Number of shares	4,028,060	4,028,060	4,028,060	4,028,060	4,028,060	4,028,060
Number of shares after dilution	4,110,060	4,159,560	4,110,060	4,159,560	4,101,810	4,151,310
Full time equivalents FTE (employees)	20	22	21	22	20	22

Definitions

Operating result (EBIT)

Operating result before interest and taxes is defined as profit before net financial items and taxes.

Operating result (EBIT) margin

Operating result (EBIT) as a percentage of net sales and other operating income.

EBITDA

Operating result before interest, taxes, depreciation, and amortization, defined as Income before net financial items, taxes and depreciation/ amortization and impairment of tangible and intangible assets.

EBITDA margin

EBITDA as a percentage of net sales and other operating income.

Earnings per share

Net income after tax for the period divided by the average number of shares during the period.

Equity per share

Equity divided by the average number of shares at the end of the period.



Average number of shares

The average number of shares is calculated on the basis of a weighted average of number of shares at the month-ends during the period.

Capital employed

Defined as total assets less non-interest-bearing liabilities.

Return on equity

Defined as operating result plus interest income rolling twelve months divided by the average equity during the period. When calculating the quarterly figure, the operating result plus interest income for the last quarter is annualized and divided by the average equity of the last quarter.

Return on capital employed

Defined as operating result plus interest income rolling twelve months divided by the average capital employed during the period. When calculating the quarterly figure, the operating result plus interest income for the last quarter is annualized and divided by the average capital employed of the last quarter.

Net debt (-) / Net cash (+)

Gross debt less cash & cash equivalents.

Debt vs Equity ratio

Defined as debt divided by equity.

Equity ratio, %

Equity as a percentage of total assets.

Additional information on definitions is disclosed in the prospectus on the company's website www.qlocore.com.